Albert Bourla's most recent trade in Pfizer Inc. was a trade of 25 Phantom Stock Units SSP done . Disclosure was reported to the exchange on June 30, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2025 | 25 | 718,220 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jun 2025 | 24 | 718,048 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 May 2025 | 26 | 718,866 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2025 | 27 | 719,518 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2025 | 25 | 705,968 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2025 | 45 | 707,396 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 1,484 | 707,507 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2025 | 24 | 705,510 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2025 | 1,905 | 705,449 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Mar 2025 | 1,487,296 | 1,487,296 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 31.31 per share. | 27 Feb 2025 | 582,823 | 931,744 (0%) | 0% | 31.3 | 18,248,188 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 582,823 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.06 per share. | 27 Feb 2025 | 545,855 | 367,589 (0%) | 0% | 26.1 | 14,224,981 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.10 per share. | 27 Feb 2025 | 18,300 | 913,444 (0%) | 0% | 26.1 | 477,630 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 22 Feb 2025 | 238,399 | 570,436 (0%) | 0% | 30.2 | 7,192,498 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Feb 2025 | 238,399 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.08 per share. | 22 Feb 2025 | 212,680 | 348,921 (0%) | 0% | 26.1 | 5,546,694 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.30 per share. | 22 Feb 2025 | 8,835 | 561,601 (0%) | 0% | 26.3 | 232,361 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 625 | 702,791 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jan 2025 | 75 | 690,650 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Dec 2024 | 20 | 690,585 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Dec 2024 | 21 | 690,626 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Nov 2024 | 20 | 690,388 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2024 | 21 | 691,116 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2024 | 19 | 679,129 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2024 | 18 | 679,044 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Oct 2024 | 69 | 679,059 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2024 | 18 | 679,014 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 413,280 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 413,280 | 413,280 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 412,081 | 412,081 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Sale or transfer of securities back to the company at price $ 0.00 per share. | 12 Sep 2024 | 412,081 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Sep 2024 | 18 | 678,971 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Aug 2024 | 18 | 678,847 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2024 | 18 | 678,992 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2024 | 17 | 678,116 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 18 | 669,258 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jul 2024 | 71 | 669,302 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jun 2024 | 19 | 669,291 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2024 | 19 | 669,366 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2024 | 18 | 668,712 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2024 | 18 | 668,625 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Apr 2024 | 20 | 659,681 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Apr 2024 | 20 | 659,636 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2024 | 18 | 659,517 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Mar 2024 | 19 | 659,207 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 8 | 659,156 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | 04 Mar 2024 | 88,240 | 659,573 | - | - | Phantom Stock Units SSP | ||
| Pfizer | Bourla Albert | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 644,640 | 644,640 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2024 | 569,600 | 569,600 | - | - | Stock Appreciation Rights | |
| Pfizer | Bourla Albert | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2024 | 127,674 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.34 per share. | 23 Feb 2024 | 127,674 | 439,748 (0%) | 0% | 27.3 | 3,490,607 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.37 per share. | 23 Feb 2024 | 103,178 | 327,739 (0%) | 0% | 27.4 | 2,823,982 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.76 per share. | 23 Feb 2024 | 8,831 | 430,917 (0%) | 0% | 27.8 | 245,149 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2024 | 3,127 | 571,198 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2024 | 71 | 559,231 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Dec 2023 | 18 | 559,088 | - | - | Phantom Stock Units SSP | |
| Pfizer | Bourla Albert | Director, Chairman & CEO | 15 Dec 2023 | 375,516 | 559,418 | - | - | Phantom Stock Units SSP | ||
| Pfizer | Bourla Albert | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 20 | 559,438 | - | - | Phantom Stock Units SSP | |
| Pfizer | Bourla Albert | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2023 | 17 | 183,660 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2023 | 17 | 183,659 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2023 | 17 | 181,151 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Oct 2023 | 16 | 181,110 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Oct 2023 | 61 | 181,042 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Sep 2023 | 16 | 180,995 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2023 | 15 | 180,947 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2023 | 15 | 180,914 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2023 | 15 | 180,898 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jul 2023 | 15 | 180,817 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 56 | 178,759 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Jul 2023 | 14 | 178,773 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Jun 2023 | 14 | 178,695 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2023 | 13 | 178,572 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 14 | 178,671 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 14 | 178,716 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2023 | 14 | 176,711 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Apr 2023 | 13 | 176,631 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Apr 2023 | 844 | 176,609 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 13 | 175,788 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | 15 Mar 2023 | 74,813 | 175,790 | - | - | Phantom Stock Units SSP | ||
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2023 | 1,335 | 100,977 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 41.75 per share. | 25 Feb 2023 | 43,419 | 309,058 (0%) | 0% | 41.7 | 1,812,743 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 413,280 | 413,280 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2023 | 359,681 | 359,681 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 42.38 per share. | 22 Feb 2023 | 61,994 | 352,477 (0%) | 0% | 42.4 | 2,627,306 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2023 | 2,037 | 99,558 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jan 2023 | 41 | 96,522 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Dec 2022 | 10 | 96,430 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 285,161 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Dec 2022 | 145,970 | 0 | - | - | Stock Appreciation Rights | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 30.17 per share. | 15 Dec 2022 | 133,172 | 322,734 (0%) | 0% | 30.2 | 4,017,799 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 22.89 per share. | 15 Dec 2022 | 89,156 | 411,890 (0%) | 0% | 22.9 | 2,040,781 | Common Stock |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2022 | 10 | 96,391 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Nov 2022 | 10 | 96,419 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2022 | 11 | 96,453 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 11 | 95,676 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Oct 2022 | 12 | 95,716 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2022 | 47 | 95,719 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 30 Sep 2022 | 12 | 95,645 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Sep 2022 | 11 | 95,602 | - | - | Phantom Stock Units SSP | |
| Pfizer | Albert Bourla | Director, Chairman & CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Aug 2022 | 11 | 95,623 | - | - | Phantom Stock Units SSP |